Disclosures: Marti Ortega-Ribera: Nothing to Disclose, Radhika Joshi: Nothing to Disclose, Sergi Guix-Muntet: Nothing to Disclose, Veronika Brezani: Nothing to Disclose, Prashanth Thevkar Nagesh: Nothing to Disclose, Viliam Brezani: Nothing to Disclose, Arman Patel: Nothing to Disclose, Mrigya Babuta: Nothing to Disclose, Yuan Zhuang: Nothing to Disclose, Jordi Gracia-Sancho: Gilead Sciences: Independent Contractor, Novo Nordisk: Independent Contractor, Inventiva: Independent Contractor, Barcelona Liver Bioservices: Stock privately held company, Oncomatryx: Independent Contractor, Quinton: Independent Contractor, Gyongyi Szabo: CYTA Therapeutics: Consultant, Durect Corporation: Consultant, Merck: Consultant, Pandion Therapeutics: Consultant, Pfizer: Consultant, Terra Firma: Consultant, LabCorp: Consultant, Takeda: Consultant, Surrozen: Advisor, Intercept: Advisor, Evive: Advisor, Glympse Bio, Inc (acquired by Sunbird Bio): Advisor, Satellite Biosciences: Advisor, Zomagen Bioscience/Ventyx Biosciences: Consultant, Springer Nature Group: Royalties or patent beneficiary, UpToDate Inc: Royalties or patent beneficiary 983 SAFETY, TOLERABILITY, AND OUTCOMES OF SOFOSBUVIR/VELPATASVIR IN TREATMENT OF CHRONIC HEPATITIS C VIRUS DURING PREGNANCY: INTERIM RESULTS FROM THE STORC STUDY Catherine Chappell 1 Jasmin Charles 2 Marcela Smid 2 Kara Rood 3 John Cafardi 4 Tatyana Kushner 5 Mia Biondi 6 Jordan Feld 7 Mark Yudin 8 Genevieve Eastabrook 9 Sarah Osmundson 10 Todd Davies 11 Meyn Leslie 1 Cathleen Letterio 12 Kyung min Kwon 12 Bruce Kreter 13 Sharon Hillier 1 , 1 University of Pittsburgh, 2 University of Utah, 3 Ohio State University, 4 The Christ Hospital, 5 Mount Sinai Medical Center, 6 University Health Network, 7 Toronto General Hospital, 8 Unity Health Toronto, 9 London Health Sciences Centre, 10 Vanderbilt University, 11 Marshall University, 12 Gilead Sciences, 13 Gilead Sciences, Inc
Ruvolo P, Qiu Y, Ruvolo V, Wang RY, Zeng Z, Burks J, Pan R, Hail Jr N, McQueen T, Yoo SY, Kornblau SM, and Andreeff M
Dumont NA, Bentzinger CF, Sincennes MC, Rudnicki MA
Through these mechanisms, phenolic acids help reprogram cancer cells to a less aggressive state
Hypoxia in renal tubular cells can cause tubular cell expansion, degeneration, apoptosis and cytokine production and secretion, thereby activating interstitial fibroblasts, increasing extracellular matrix production and promoting the progression of tubulointerstitial fibrosis (40)
Seeking medical attention ensures timely diagnosis and treatment, potentially preventing complications down the road
